

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/500,700	02/09/2000	Carlos F. Barbas III	SCRIP1160-4	2975	
7	7590 08/07/2002				
Lisa A Haile			EXAM	EXAMINER	
4365 Executive	re & Friedenrich LLP e Drive Suite 1100		LEFFERS JR, GERALD G		
San Diego, CA	92121-2133		ART UNIT	PAPER NUMBER	
			1636	99	
				DATE MAILED: 08/07/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.



COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, DC 20231 www.uspto.gov

APPLICATION NO./	FILING DATE	FIRST NAMED INVENTOR /	ATTORNEY DOCKET NO.
CONTROL NO.		PATENT IN REEXAMINATION	

EXAMINER				
Gerald G. Leffers Jr.				
ART UNIT	PAPER			
1636	22			

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

## **Commissioner of Patents**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gerald G. Leffers Jr. whose telephone number is (703)-308-6232. The examiner can normally be reached on Monday through Friday, 9:30 am to 6:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel can be reached at (703) 305-1998. The fax number for the organization where this application or proceeding is assigned is (703) 305-1998.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to Zeta Adams whose telephone number is (703) 305-3291.

Gerald G. Leffers Jr., PhD. Examiner, Art Unit 1636

	)						
		Application No.	Applicant(s)				
Nation to Commit		09/500,700	BARBAS III ET AL.				
	Notice to Comply	Examiner	Art Unit				
		Gerald G. Leffers Jr.	1636				
	OTICE TO COMPLY WITH REQUIREMENTS JCLEOTIDE SEQUENCE AND/OR AMINO						
Ap ave	plicant must file the items indicated below within the ti oid abandonment under 35 U.S.C. § 133 (extensions of	ime period set the Office action to of time may be obtained under the	which the Notice is attached to e provisions of 37 CFR 1.136(a)).				
	e nucleotide and/or amino acid sequence disclosure of such a disclosure as set forth in 37 C.F.R. 1.821 - 1.8		not comply with the requirements				
$\boxtimes$	☑ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).						
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).						
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).						
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."						
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).						
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).						
	7. Other: multiple sequences are present in the figu quence listing or CRF (e.g. figures 8, 9, 17 & 18).	res that lack sequence identifiers	, are not in the paper copy of the				
	oplicant Must Provide:  An initial or substitute computer readable form (CRF	) copy of the "Sequence Listing".					
	An initial or substitute paper copy of the "Sequence I ecification.	Listing", as well as an amendmen	t directing its entry into the				
	A statement that the content of the paper and comp new matter, as required by 37 C.F.R. 1.821(e) or 1.82						
Fc	or questions regarding compliance to these re	equirements, please contact	:				
Fc	or Rules Interpretation, call (703) 308-4216 or CRF Submission Help, call (703) 308-4212						
Pa	ntentIn Software Program Support  Technical Assistance	703-287-0200					

To Purchase Patentin Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY